[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100498758":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":10,"centralContacts":10,"locations":23,"responsibleParty":37,"collaborators":10,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":10,"eligibilityCriteria":47,"healthyVolunteers":43,"sex":48,"minAge":49,"maxAge":10,"enrollmentInfo":50,"targetDuration":10,"studyType":53,"phases":10,"briefSummary":54,"conditions":55,"keywords":10,"overallStatus":57,"whyStopped":10,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},{"fullName":5,"class":6},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"vaccinated",null,"Healthcare workers (aged ≥18 years) working at hospital sites who could provide written informed consent and who will complete the immunization program with the administration of the second dose after approximately 21 days from the first dose at the FPG",[13],"Biological: BNT162b2 COVID-19 Vaccine",{"label":15,"type":10,"description":16,"interventionNames":10},"unvaccinated","unvaccinated health workers",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"BIOLOGICAL","BNT162b2 COVID-19 Vaccine","BNT162b2 is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people from the age of 18 years. BNT162b2 contains tozinameran, a messenger RNA (mRNA) molecule with instructions for producing a protein from the original strain of SARS-CoV-2, the virus that causes COVID-19. BNT162b2 is given as two injections, usually into the muscle of the upper arm, 3 weeks apart.",[9],[24],{"facility":25,"status":10,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":10},"Fondazione Policlinico Universitario \"A. Gemelli\" IRCCS","Roma","RM","00168","Italy","IT",{"type":32,"coordinates":33},"Point",[34,35],11.10642,44.99364,{"lat":35,"lon":34},{"type":38,"investigatorFullName":39,"investigatorTitle":40,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Laurenti Patrizia","Professor","100498758","evaluation-of-the-impact-of-the-anti-covid-19-vaccination-campaign-addressed-to-the-employees-of-an-italian-hospital-100498758",false,"NCT05774418","Evaluation of the Impact of the Anti COVID-19 Vaccination Campaign Addressed to the Employees of an Italian Hospital.","Evaluation of the Effectiveness and Safety of the BNT162b2 COVID-19 Vaccine in the Vaccination Campaign Among the Health Workers of Fondazione Policlinico Universitario Agostino Gemelli IRCCS","Inclusion Criteria:\n\n* Healthcare workers (aged ≥18 years) working at hospital sites who could provide written informed consent and who completed the immunization program with the administration of the second dose after approximately 21 days from the first dose at the FPG will be included\n\nExclusion Criteria:\n\n* Participants were excluded from this analysis if they either will have a positive PCR test after 31 December 2020 and had clinical contraindications to the administration of the vaccine.","ALL","18 Years",{"count":51,"type":52},6649,"ACTUAL","OBSERVATIONAL","Health workers, especially those in patient-facing roles, had a significantly increased risk of COVID-19 infection, having serious outcomes, and risking spreading the virus to patients and staff. Vaccination campaign planning suggests allocating initial supplies of BNT162b2 vaccine to health workers given the importance of early protection to safeguard the continuity of care to patients. The aim of the study is to assess the effectiveness and safety of BNT162b2 vaccine among the health workers of Fondazione Policlinico Universitario Agostino Gemelli IRCCS (FPG). The retrospective cohort study will be conducted among health staff working at the FPG. Vaccination data will collect from hospital records. The primary end points will be vaccine effectiveness and safety.",[56],"COVID-19","COMPLETED","2023-03-15",{"date":60,"type":52},"2023-03-17",{"date":62,"type":52},"2020-12-28",{"date":64,"type":52},"2021-03-31",{"name":5,"class":6},1]